EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieStudienprotokollOpen Access · CC BY 4.0

Multi‐omics profiling of chronic immune‐mediated skin diseases: SKINERGY protocol and strategic evaluation

N G Koster iD, J M P A van den Reek iD, E M G J de Jong, S van Beugen, A I M van Laarhoven, I Haeck, M de Bruin-Weller, M L Schuttelaar, B Horvath, A Gostyński iD, A Knulst, M H Vermeer iD und 33 weitere

Journal of the European Academy of Dermatology and Venereology · 2026-09 · 40 (9) · 1490-1501

DOI: 10.1111/jdv.70311 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 06.02.2026. Verfasst von N G Koster und 44 weiteren Autor:innen. Beteiligte Einrichtung: Division BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Multiomics, Skin Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nederlandse Organisatie voor Wetenschappelijk Onderzoek.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The Dutch flagship project Next Generation ImmunoDermatology (NGID) aims to profile five chronic immune‐mediated inflammatory skin diseases: atopic dermatitis (AD), plaque psoriasis (PSO), hidradenitis suppurativa (HS), chronic spontaneous urticaria (CSU) and cutaneous lupus erythematosus (CLE) in comparison with cutaneous T‐cell lymphoma subtype mycosis fungoides (MF) and healthy volunteers. Within NGID, a clinical study entitled: ‘SKIN disease profiling by an Exploratory, pRospective, biomarker study in dermatoloGY practice (SKINERGY)’ will be conducted as a multicentre, parallel‐cohort, open‐label, observational, longitudinal basket study.

Objectives

Objectives include evaluation of disease‐related characteristics in comparison to those of healthy volunteers and evaluation of biomarkers for disease stratification and (targeted) treatment response in patients in a real‐world clinical setting. Additionally, differences and similarities in disease characteristics between diseases, changes over time, and profiles of responders versus non‐responders will be evaluated.

Methods

Patients with AD ( N = 120), PSO ( N = 160), HS ( N = 80), CSU (N = 120) and CLE (N = 120) will be enrolled in groups of N ≤ 40 patients per treatment. Matched healthy volunteers (N = 120) and the MF cohort (N = 120) will serve as control groups. Assessments include blood sampling, skin punch biopsies, tape stripping, skin swabs, (multimodal) imaging, tele‐health and patient‐ and physician‐reported outcomes. This manuscript describes the study protocol prior to data collection and its strategic evaluation of multi‐omics profiling. Patient advocacy groups co‐defined the research agenda and contributed to study design and informed consent document development, ensuring alignment with patients' needs and real‐world relevance.

Results

SKINERGY will generate a machine learning‐ready dataset with information about changes in various biomarkers over time, including histology, metabolomics, spatial proteomics, transcriptomics, lipidomics, microbiomics, imaging biomarkers, tele‐health, patient‐reported outcome measures (PROMs) and clinical parameters.

Conclusions

Identified biomarker profiles within SKINERGY may guide targeted treatment selection, enhance targeted therapeutic response in clinical practice and improve understanding of disease pathology in chronic immune‐mediated skin diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MultiomicsSkin DiseasesHumansMaleBiomarkersChronic DiseaseChronic UrticariaDermatitis, AtopicHidradenitis SuppurativaLongitudinal StudiesLupus Erythematosus, CutaneousMycosis FungoidesProspective StudiesPsoriasis

Stichwörter der Autor:innen

atopic dermatitischronic spontaneous urticariacutaneous lupus erythematosushidradenitis suppurativainflammatory skin diseasesmulti‐omics deep phenotypingmycosis fungoides‐type cutaneous t‐cell lymphomapersonalized medicinepsoriasis

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Division BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.
  • Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands.
  • Centre for Human Drug Research (CHDR), Leiden, The Netherlands.
  • Dept. Dermatology, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Leiden University, Institute of Psychology, Health, Medical and Neuropsychology Unit, Leiden, The Netherlands.
  • Department of Dermatology, University Medical Center Utrecht, Utrecht, The Netherlands.

ORCID-Profile: N G Koster, J M P A van den Reek, A Gostyński, M H Vermeer, T Niemeyer-van der Kolk, B W M Arents, M Maurer, H van der Zee, J Damman, M M B Seyger

Förderung

  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek

Zitieren

APA

Koster, N. G., van den Reek, J. M. P. A., de Jong, E. M. G. J., van Beugen, S., van Laarhoven, A. I. M., Haeck, I., de Bruin-Weller, M., Schuttelaar, M. L., Horvath, B., Gostyński, A., Knulst, A., Vermeer, M. H., Nguyen, L., Gerbens, L., Spuls, P., Middelkamp-Hup, M. A., Exadaktylos, V., Niemeyer-van der Kolk, T., Schrader, A. R., …, & Next Generation ImmunoDermatology (NGID) consortium (2026). Multi‐omics profiling of chronic immune‐mediated skin diseases: SKINERGY protocol and strategic evaluation. Journal of the European Academy of Dermatology and Venereology, 40(9), 1490-1501. https://doi.org/10.1111/jdv.70311

Vancouver

Koster NG, van den Reek JMPA, de Jong EMGJ, van Beugen S, van Laarhoven AIM, Haeck I, et al. Multi‐omics profiling of chronic immune‐mediated skin diseases: SKINERGY protocol and strategic evaluation. Journal of the European Academy of Dermatology and Venereology. 2026;40(9):1490-1501. doi:10.1111/jdv.70311

BibTeX
@article{Koster2026,
  author = {Koster, N G and van den Reek, J M P A and de Jong, E M G J and van Beugen, S and van Laarhoven, A I M and Haeck, I and de Bruin-Weller, M and Schuttelaar, M L and Horvath, B and Gostyński, A and Knulst, A and Vermeer, M H and Nguyen, L and Gerbens, L and Spuls, P and Middelkamp-Hup, M A and Exadaktylos, V and Niemeyer-van der Kolk, T and Schrader, A R and Sluijmers, A M and Versteeg, J and Arents, B W M and van Ee, I and van der Zon, J L A G and de Leeuw, M and de Leeuw, T and van den Broek, P and Berkhof, C and Vellinga, D and Weidinger, S and Dubrac, S and Li, Y and van Steensel, M and Marchetti-Deschmann, M and Maurer, M and van der Zee, H and Damman, J and Hijnen, D J and Wijk, F and Seyger, M M B and Röckmann, H and Balak, D M W and van Doorn, M B A and Rissmann, R and Next Generation ImmunoDermatology (NGID) consortium, Next Generation ImmunoDermatology (NGID) consortium},
  title = {Multi‐omics profiling of chronic immune‐mediated skin diseases: SKINERGY protocol and strategic evaluation},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2026},
  volume = {40},
  number = {9},
  pages = {1490--1501},
  doi = {10.1111/jdv.70311}
}
Kostenlos starten →